// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

“Diagnostic Burn‐out” for Hepatitis C: when will countries run out of diagnosed people to treat with DAAs?

Andrew M. Hill - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug (PWID) in the United States (US): a mathematical model using data from the C‐EDGE CO‐STAR Study

Yiling Jiang - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Liver cancer

Elbasvir + grazoprevir

The development of liver disease in childhood acquired hepatitis C infection in the UK

Line Modin - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

VirA+EmiC project: universal Hepatitis C and B screening with integrated linkage to care in an urban London emergency department ‐ interim results

Barnaby F. Flower - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Hepatitis C (HCV) in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response (SVR) on Patient‐Reported Outcomes (PROs)

Zobair M. Younossi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Project ITTREAT (Integrated Community Based Test ‐ stage‐TREAT HCV Service) for People who Inject Drugs: Year 3 Results

Margaret O'Sullivan - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

HepFree: A large cluster randomised controlled cross sectional trial to assess screening and treating first and second generation migrants from ‘At Risk’ countries with chronic viral hepatitis

Stuart Flanagan - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Regression of Fibrosis after Hepatitis C Treatment ‐ A Step Towards Discharge?

Michael Johnston - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

Interferon

Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1‐4 HCV‐Infected Liver Transplant Recipients

Kosh Agarwal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

Velpatasvir/sofosbuvir

Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study

Marianne Martinello - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

paritaprevir

An analysis of potential elimination strategies for hepatitis C using a budget optimization model for the UK

Olivier Ethgen - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Bioequivalent pharmacokinetics for generic and originator Hepatitis C Direct Acting Antivirals

Andrew M. Hill - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

daclatasvir

Safety and Efficacy of Direct Acting Antivirals: UK Real World Experience from a Large Well Characterised Predominantly Cirrhotic HCV Cohort

Lucia Macken - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Hepatitis B reactivation during DAA therapy for Hepatitis C ‐ does it affect clinical outcomes?

Ruth Byrne - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatitis B

Lamivudine

Real‐World Cost‐Effectiveness Of Elbasvir/ Grazoprevir (EBR/GZR) In Treatment‐Naive (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) In The United States (US)

Shelby L. Corman - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

grazoprevir

Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1‐6 and Recent Drug Use

Graham R. Foster - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

Glecaprevir and Pibrentasvir

Safety and Efficacy of Glecaprevir/Pibrent‐ asvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials

Graham R. Foster - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

Glecaprevir

The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple‐dose, open‐label, multinational study

Ekkehard Sturm - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

A4250

Validating the Mayo model of primary sclerosing cholangitis outcomes in children: data from the Pediatric PSC Consortium

Mark R. Deneau - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary sclerosing cholangitis

N/A

Use of a Comprehensive 66 Gene Panel to Diagnose the Causes of Cholestasis in >700 Individuals

Saul J. Karpen - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

N/A

Copyright © 2026. QuantiNova All rights reserved